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Abstract
Background: Little information is available on the molecular epidemiology in Mexico of Mycobacterium species infecting
extrapulmonary sites in humans. This study used molecular methods to determine the Mycobacterium species present in
tissues and body fluids in specimens obtained from patients in Mexico with extrapulmonary disease.
Methods:  Bacterial or tissue specimens from patients with clinical or histological diagnosis of extrapulmonary
tuberculosis were studied. DNA extracts from 30 bacterial cultures grown in Löwenstein Jensen medium and 42 paraffin-
embedded tissues were prepared. Bacteria were cultured from urine, cerebrospinal fluid, pericardial fluid, gastric
aspirate, or synovial fluid samples. Tissues samples were from lymph nodes, skin, brain, vagina, and peritoneum. The DNA
extracts were analyzed by PCR and by line probe assay (INNO-LiPA MYCOBACTERIA v2. Innogenetics NV, Gent,
Belgium) in order to identify the Mycobacterium species present. DNA samples positive for M. tuberculosis complex were
further analyzed by PCR and line probe assay (INNO-LiPA Rif.TB, Innogenetics NV, Gent, Belgium) to detect mutations
in the rpoB gene associated with rifampicin resistance.
Results: Of the 72 DNA extracts, 26 (36.1%) and 23 (31.9%) tested positive for Mycobacterium species by PCR or line
probe assay, respectively. In tissues, M. tuberculosis complex and M. genus were found in lymph nodes, and M. genus was
found in brain and vagina specimens. In body fluids, M. tuberculosis complex was found in synovial fluid. M. gordonae, M.
smegmatis, M. kansasii, M. genus, M. fortuitum/M. peregrinum complex and M. tuberculosis complex were found in urine. M.
chelonae/M. abscessus was found in pericardial fluid and M. kansasii was found in gastric aspirate. Two of M. tuberculosis
complex isolates were also PCR and LiPA positive for the rpoB gene. These two isolates were from lymph nodes and
were sensitive to rifampicin.
Conclusion: 1) We describe the Mycobacterium species diversity in specimens derived from extrapulmonary sites in
symptomatic patients in Mexico; 2) Nontuberculous mycobacteria were found in a considerable number of patients; 3)
Genotypic rifampicin resistance in M. tuberculosis complex infections in lymph nodes was not found.
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Background
The genus Mycobacterium has been classified into many
species [1]. A group of Mycobacterium species called M.
tuberculosis complex that comprise M. tuberculosis, M. bovis,
M. microti, and M. africanum is of utmost clinical impor-
tance since it causes tuberculosis in humans worldwide
[2-4]. Mycobacterium species other than those of the tuber-
culosis complex, also called nontuberculous mycobacte-
ria, are widely distributed in the environment and may
colonize and occasionally cause infections in humans [5-
7]. Mycobacteria of the M. tuberculosis complex and non-
tuberculous mycobacteria have been found to cause infec-
tions in immunocompetent and immunocompromised
subjects and cause pathology in pulmonary and extrapul-
monary sites [8-11]. Most epidemiological studies on
mycobacteria have been focused on pulmonary infec-
tions, while extrapulmonary infections have been poorly
explored. Extrapulmonary tuberculosis accounts for about
10% to 20% of tuberculosis cases in immunocompetent
subjects but this frequency increases markedly in immu-
nocompromised subjects [12]. Extrapulmonary sites are
affected in up to 60% of patients suffering from acquired
immunodeficiency syndrome and tuberculosis [12].
Molecular diagnosis of mycobacterial infections has ena-
bled rapid detection of species in clinical specimens,
detection of drug resistance, and typing for epidemiologi-
cal studies [4,6,9,13]. Little is known on the worldwide
molecular epidemiology of Mycobacterium species infect-
ing extrapulmonary sites. In addition, genotypic resist-
ance to drugs in M. tuberculosis isolates from
extrapulmonary sites has been poorly studied. There is
scarce information on the molecular epidemiology in
Mexico of Mycobacterium species infecting extrapulmonary
sites. Therefore, in this study on samples obtained from
such patients, we used molecular methods to identify the
Mycobacterium species in tissue samples and body fluids.
In addition, we analyzed the gene encoding for the β-sub-
unit of the RNA polymerase (rpoB) for identification of
mutations associated with rifampicin resistance in DNA
extracts positive for M. tuberculosis complex.
Methods
Patients and specimens
Seventy-two patients with clinical or histological findings
compatible with extrapulmonary tuberculosis were stud-
ied. Patients attended four public hospitals in the Mexican
cities of Durango, Zacatecas and Guadalajara. Durango
City is located in north central Mexico, while Zacatecas
and Guadalajara Cities are located in central Mexico.
Specimens from the patients were prepared as either par-
affin-embedded tissue or cultures of body fluids. For par-
affin-embedded tissues, we studied recent and stored
specimens obtained from the pathology departments of
two hospitals from 2002 to 2008. In total, tissues of 42
patients were studied: twelve of them were obtained in
Durango City and 30 in Zacatecas City. For body fluids,
we studied recent and stored cultures in Löwenstein
Jensen medium from urine, pericardial fluid, gastric aspi-
rate, synovial fluid and cerebrospinal fluid obtained from
30 patients. These specimens were obtained in two hospi-
tals in Guadalajara City from 2007 to 2008. The studied
specimens were obtained only from the participating hos-
pitals and are not representative of specimens from all
hospitals in these cities. DNA was extracted from all spec-
imens using a commercially available kit (QIAamp DNA
Mini Kit, QIAGEN. Germany) following the instructions
of the manufacturer. Prior to extraction, paraffin-embed-
ded tissues were treated with xylene and alcohol to
remove the paraffin, and bacterial cultures were heated at
95°C for 10 minutes.
Molecular analysis of Mycobacterium species
DNA extracted from the 72 specimens was amplified by
PCR using the INNO-LiPA MYCOBACTERIA v2 Amp.
(Innogenetics NV, Gent, Belgium) kit according to the
manufacturers' instructions. PCR parameters were: dena-
turation at 95°C for 1 min followed by 40 cycles of dena-
turation at 95°C for 30 sec, annealing at 62°C for 30 sec,
and extension at 72°C for 30 sec. Electrophoresis of
amplified products was performed in a 2% agarose gel.
The gel was then stained with ethidium bromide and vis-
ualized by ultraviolet transillumination. In addition,
amplified products were analyzed by line probe assay
(INNO-LiPA MYCOBACTERIA v2. Innogenetics NV,
Gent, Belgium) following the manufacturers' instructions.
This DNA probe test targets the 16S–23S ribosomal RNA
spacer region and detects and identifies the genus Myco-
bacterium  and 16 different mycobacterial species. As a
quality control for amplifications, we included water sam-
ples as negative controls, and M. tuberculosis complex
DNA as positive controls in each run.
Analysis of rifampicin resistance of M. tuberculosis
Amplification of the rifampicin resistance region of the
gene encoding for the β-subunit of the RNA polymerase
(rpoB) in DNA samples positive for M. tuberculosis com-
plex by INNO-LiPA MYCOBACTERIA v2 was performed
using the INNO-LiPA Rif.TB Amplification kit (Innoge-
netics NV, Gent, Belgium). The PCR parameters were
denaturation at 95°C for 5 min followed by 30 cycles of
denaturation at 95°C for 1 min, annealing at 55°C for 1
min, extension at 72°C for 1 min, and an elongation at
72°C for 10 min. After electrophoresis of the amplified
products in 2% agarose gel, the gel was stained with ethid-
ium bromide and visualized by ultraviolet transillumina-
tion. In addition, amplification products were analyzed
by line probe assay (INNO-LiPA Rif.TB. Innogenetics NV,
Gent, Belgium) for detection of rifampicin resistance. This
assay was performed following the manufacturers'
instructions. As a quality control for amplifications, weBMC Clinical Pathology 2009, 9:1 http://www.biomedcentral.com/1472-6890/9/1
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included water samples as negative controls, and M. tuber-
culosis complex DNA as positive controls in each run.
Results and discussion
Rate of positive PCR and LiPA samples
As shown in Tables 1 and 2, only 26 (36.1%) and 23
(31.9%) of the 72 DNA extracts were PCR positive for the
16S–23S ribosomal RNA spacer region of Mycobacterium
species and LiPA hybridization, respectively. The low rate
of positive samples could be explained by: 1) No Mycobac-
terium  species were present in the samples: pathology
diagnosis is not conclusive of tuberculosis; 2) DNA of
Mycobacterium was present in the tissues but at levels that
were undetectable by a single-round PCR assay; 3) DNA
preservation in some samples was sub-optimal; and 4) the
presence of PCR inhibitors. Most samples tested were
archival and a comparable rate of positive PCR results in
archival tissue samples was reported in a previous study
[14]. Moreover, our study was based in a single determi-
nation and it is possible that repeating assays could
increase the rate of positive samples.
Mycobacterium species
Table 1 shows the Mycobacterium species identified in par-
affin-embedded tissues, and Table 2 shows results
obtained for body fluids. In paraffin-embedded tissues,
Table 1: Clinical and histological data of paraffin embedded tissues from the study population.
Case No. Age Gender Place of origin Clinical diagnosis Specimen Pathology diagnosis ZN staining PCR Mycobacteria
T1 39 M Dgo TB Brain TB + + M. genus
T2 34 M Dgo Tumour Lymph node TB + + M. tuberculosis complex
T3 42 M Dgo Lymphadenitis Lymph node TB - -
T4 45 F Dgo Tumour Vagina TB + + M. genus
T5 45 M Dgo Lymphadenitis Lymph node TB + + M. genus
T6 18 M Dgo Tumour Lymph node TB + -
T7 40 M Dgo TB Lymph node TB - -
T8 13 M Dgo Acute abdomen Epiplon TB + -
T10 21 F Dgo Lymphadenitis Lymph node TB - -
T11 29 M Dgo Lymphadenitis Lymph node TB ND -
T12 16 M Dgo Acute abdomen Peritoneum TB - -
T14 20 M Dgo Epidermic cyst Skin TB + -
T41 9 F Zac Granuloma Lymph node TB + + M. tuberculosis complex
T42 57 M Zac Granuloma Lymph node TB ND -
T43 31 M Zac TB Lymph node TB + - M. tuberculosis complex
T44 56 M Zac Granuloma Lymph node TB ND - M. genus
T45 1 M Zac Granuloma Lymph node TB ND - M. genus
T46 39 M Zac Granuloma Lymph node TB + -
T47 39 M Zac Granuloma Lymph node TB + -
T48 1 M Zac Granuloma Lymph node TB + -
T49 53 M Zac Lymphoma Lymph node Lymphoma ND -
T50 1 F Zac Granuloma Lymph node TB ND -
T51 1 M Zac Granuloma Lymph node TB ND -
T52 62 F Zac Hyperplasia Lymph node Hyperplasia ND -
T53 19 M Zac Lymphoma Lymph node TB ND -
T54 67 F Zac Lymphoma Lymph node Lymphoma ND - M. tuberculosis complex
T55 37 F Zac Hyperplasia Lymph node Hyperplasia ND - M. tuberculosis complex
T56 4 M Zac Granuloma Lymph node Lymphoma ND -
T57 44 F Zac Granuloma Lymph node TB + -
T58 32 F Zac Granuloma Lymph node TB ND -
T59 32 F Zac Granuloma Lymph node TB + -
T60 74 F Zac Granuloma Lymph node TB + -
T61 38 M Zac Granuloma Lymph node TB + -
T62 9 M Zac Granuloma Lymph node TB ND -
T63 0.4 M Zac Granuloma Lymph node TB ND +
T64 53 F Zac Granuloma Lymph node TB + -
T65 45 F Zac Granuloma Lymph node TB ND -
T66 1 M Zac Granuloma Lymph node TB + -
T67 3 M Zac Granuloma Lymph node TB ND -
T68 54 F Zac Granuloma Lymph node TB ND -
T69 72 F Zac Lymphoma Lymph node Lymphoma ND -
T70 28 F Zac Granuloma Lymph node TB ND -
ND: Not done. Dgo: Durango. Zac: Zacatecas.BMC Clinical Pathology 2009, 9:1 http://www.biomedcentral.com/1472-6890/9/1
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M. tuberculosis complex and M. genus were found in 5 and
3 lymph nodes, respectively. The predominant M. tubercu-
losis  complex infection in lymph nodes found in our
patients is consistent with results in patients with lym-
phadenitis reported by other researchers [4,15,16]. With
respect to other tissues, M. genus was found in specimens
of brain and vagina. Hybridization with M. genus probes
indicates that amplified DNA belongs to mycobacteria but
it is not one of the 16 Mycobacterium species included in
the kit. In body fluids, M. tuberculosis complex and nontu-
berculous mycobacteria were found in 1 (10%) and 9
(90%) of urine samples with positive hybridization,
respectively. The frequency of M. tuberculosis complex
infection in these patients is lower than that reported in a
study performed in Turkey, where 12 (70.5%) of 17
strains isolated from urine cultures of patients with sus-
pected urinary tuberculosis were identified as M. tubercu-
losis  complex [17]. The finding of a high frequency of
nontuberculous mycobacteria in urine may indicate con-
tamination by mycobacteria in the environment. Never-
theless, all urine samples were obtained from
symptomatic subjects with clinical diagnosis of renal
tuberculosis and had obtained clinical improvement after
anti-tuberculosis therapy. Many nontuberculous myco-
bacteria have recently been recognized as pathogenic [18].
The species of nontuberculous mycobacteria found in the
urine of our patients have been found in symptomatic
patients in several studies: 1) M. fortuitum was found in 2
of 5 renal transplant recipients with urinary symptoms
[19]; 2) a case report of a woman suffering from urinary
complaints describes that M. tuberculosis and other patho-
gens were not detected, but that M. gordonae was repeat-
edly isolated from urine. The patient responded to a
standard anti-tuberculosis regimen [20]; and 3) positive
urine culture for M. kansasii in patients with persistent
fever who were suffering from hairy cell leukemia and dis-
seminated atypical mycobacterial infection [21]. On the
other hand, M. smegmatis has been isolated from skin and
soft tissue infections [22], but to the best of our knowl-
edge there is not any report of its isolation in urine from
patients with urinary disease. The finding of nontubercu-
lous mycobacteria in any specimen should always be cor-
related with clinical data of the patients to make
appropriated therapeutic decisions. Since most Mycobacte-
Table 2: Clinical data of patients with Löwenstein Jensen cultures strains.
Case No. Age Gender Clinical diagnosis Specimen ZN staining PCR Mycobacteria
C1 65 M RTB Urine - -
C2 10 M RTB Urine + +
C3 39 F RTB Urine + + M. gordonae
C4 29 M RTB Urine ND +
C5 48 F RTB Urine + -
C6 29 F RTB Urine + -
C7 12 M RTB Urine + -
C8 23 F RTB Urine - -
C9 79 F RTB Urine + -
C10 23 F RTB Urine ND +
C11 20 M TB Pericardial fluid ND + M. chelonae complex group III. M. abscessus
C12 29 F RTB Urine ND + M. tuberculosis complex
C13 38 F RTB Urine - + M. smegmatis
C14 53 F RTB Urine - + M. smegmatis
C15 63 F RTB Urine + - M. smegmatis
C16 13 F RTB Urine ND + M. kansasii group II
C17 3 F RTB Urine ND + M. genus
C18 35 F TB Gastric aspirate ND + M. kansasii group I
C19 9 F RTB Urine ND +
C20 13 F RTB Urine ND + M. fortuitum-M. peregrinum complex
C21 48 F RTB Urine + + M. smegmatis
C22 34 F RTB Urine ND + M. genus
C23 23 F RTB Urine ND +
C24 29 M RTB Urine ND +
C25 35 M RTB Urine ND +
C26 10 M RTB Urine + -
C27 1 F TB CSF + -
C28 30 F TB Synovial fluid + + M. tuberculosis complex
C29 45 M TB CSF - -
C30 56 F RTB Urine + +
CSF: Cerebrospinal fluid
RTB: Renal tuberculosisBMC Clinical Pathology 2009, 9:1 http://www.biomedcentral.com/1472-6890/9/1
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rium species found in extrapulmonary specimens in our
symptomatic patients did not belong to the M. tuberculosis
complex, our results emphasize the importance of per-
forming identification of mycobacterial species. Discrimi-
nation of infecting Mycobacterium  species is important
since treatment differs [23]. PCR and LiPA technology has
been successfully used in identifying both Mycobacterium
species and rifampicin resistance in M. tuberculosis isolates
in either Mycobacterium  grown in culture or directly in
some clinical samples [24-27]. However, this study is the
first to identify and classify Mycobacterium species and to
detect genotypic rifampicin resistance from paraffin-
embedded tissues by using LiPA technology. In addition,
this is the first report of Mycobacterium species diversity
detected by molecular methods in symptomatic patients
in Mexico suffering from extrapulmonary disease. Our
results indicate that LiPA can be used successfully in ana-
lyzing DNA extracts of paraffin-embedded tissues.
Rifampicin resistance
Two of the seven M. tuberculosis complex samples were
positive for amplification of the rpoB gene and showed
hybridization patterns compatible with wild type M.
tuberculosis. Samples negative for LiPA were not further
analyzed. The two positive samples were obtained from
lymph nodes and were considered sensitive to rifampicin.
These results further provide molecular characterization
of the M. tuberculosis complex isolates. Patients suffering
from extrapulmonary tuberculosis have a delay in diagno-
sis [28]. Therefore, fast molecular analysis of Mycobacte-
rium  using LiPA technology provides an aid for rapid
diagnosis and the opportunity to take optimal preventive
and treatment measures.
Conclusion
1) We describe the Mycobacterium species diversity in spec-
imens derived from extrapulmonary sites in symptomatic
patients in Mexico; 2) Nontuberculous mycobacteria were
found in a considerable number of patients; 3) genotypic
rifampicin resistance in M. tuberculosis complex infections
in lymph nodes was not found.
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